GroVida
About Alaskan Thunder Fuck (aka. Matanuska Thunder Fuck, Humble Warrior)
ATFSativa HybridLegend has it that this variety is grown in the grasslands of Alaska’s Matanuska Valley and without breeders or specific genetics to point to, this bud brings an air of mystery to everyone who dares enjoy her.
American Genetics, 
Russian Genetics
Alaskan Thunder Fuck, also known as 'Matanuska Thunder Fuck', and as 'Humble Warrior.'
Newer users may be pretty intimidated by this strain’s name, but in fact, Matanuska Thunder Fuck is a fairly gentle bud. Legend has it that this variety is grown in the grasslands of Alaska’s Matanuska Valley and without breeders or specific genetics to point to, this bud brings an air of mystery to everyone who dares enjoy her.
Also known as M.T.F., this strain typically measures between 13% and 16% THC with the occasional batch testing at just over 20%. Nugs are a very bright green and although their pistil coverage is a bit lacking, a wealth of white trichomes resemble a fresh blanket of snow. Both flavours and aromas match each other seamlessly, and many find that they’re very attracted to the blend of chocolate and fruit that Matanuska Thunder Fuck presents.
Known as Matanuska Tundra outside of the United States.
Information provided could come from a third-party source, and may not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).
About Lyphe Group Ltd
From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.
At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.
lyphegroup.com
Further National Health-Service Information on